Trajectories of Blood Pressure Elevation Preceding Hypertension Onset
An Analysis of the Framingham Heart Study Original Cohort

Teemu J. Niiranen, MD; Mir Henglin, BA; Brian Claggett, PhD; Vito M. R. Muggeo, PhD; Elizabeth McCabe, PhD; Mohit Jain, MD, PhD; Ramachandran S. Vasan, MD; Martin G. Larson, SD; Susan Cheng, MD, MPH

IMPORTANCE Given that hypertension remains a leading risk factor for chronic disease globally, there are substantial ongoing efforts to define the optimal range of blood pressure (BP).

OBJECTIVE To identify a common threshold level above which BP rise tends to accelerate in progression toward hypertension.

DESIGN, SETTING, AND PARTICIPANTS This longitudinal, community-based epidemiological cohort study of adults enrolled in Framingham, Massachusetts, included 1252 participants (mean [SD] age, 35.3 [2.7] years) from the Framingham Original Cohort, of whom 790 (63.1%) were women. Each participant contributed up to 28 serial examinations of standardized resting BP measurements between 1948 and 2005.

EXPOSURES Age and systolic BP.

MAIN OUTCOMES AND MEASURES Via a segmented mixed model, we identified significant change points in the association between advancing age and increasing systolic BP among individuals categorized by their age of hypertension onset.

RESULTS Individuals maintained a relatively stable resting systolic BP level prior to hypertension onset. Systolic BP level began to rise at a more rapid rate after reaching a level of 123.2 mm Hg (95% CI, 122.7-130.1 mm Hg) in people with onset at 40 to 49 years; 122.0 mm Hg (95% CI, 120.3-123.9 mm Hg) in those with onset between 50 and 59 years, 124.9 mm Hg (95% CI, 120.2-127.9 mm Hg) in those with onset between 60 and 69 years, and 120.5 mm Hg (95% CI, 118.0-123.2 mm Hg) in those with onset between 70 and 79 years (P = .29 for between-group heterogeneity).

CONCLUSIONS AND RELEVANCE We observed that individuals in the community generally maintained a systolic BP of less than 120 to 125 mm Hg, above which systolic BP increased at a relatively rapid rate toward overt hypertension. This trend was consistent whether the hypertension manifested earlier or later in life. Thus, a resting systolic BP that chronically exceeds the range of approximately 120 to 125 mm Hg may represent an important threshold of underlying vascular remodeling and signal incipient hypertension irrespective of age. Further investigations are needed to unravel the sequence of hemodynamic and vascular changes occurring prior to hypertension onset.
The widespread burden of hypertension and its associated risk for multisystem end-organ damage has prompted substantial ongoing efforts to define the optimal range of blood pressure (BP). The general understanding of normal BP has evolved greatly since the 1970s, when the age of a person plus 100 mm Hg was considered acceptable for systolic BP. Nonetheless, incremental elevations in systolic BP during the life course are still commonly believed to be a largely unavoidable feature of biological aging (Figure 1A).

Challenging this notion are experimental data suggesting that, while many disease traits are age-related, their onset of development may be effectively delayed by biological resilience (the preservation of health despite chronic exposure to stressors) (Figure 1B). In this paradigm, the onset of BP elevation might occur at an earlier or a later age, at which point BP starts to rise at a relatively rapid rate. As such, the timing and nature of the disease onset, rather than its progression, would be especially important to understand and target for intervention. In turn, more frequent clinical assessments might be warranted to monitor for a rapid progression to hypertension once BP elevation is detected at a certain threshold.

Our objective was therefore to elucidate the natural history of BP elevation in individuals with varying ages of hypertension onset. We focused particularly on discovering distinct change points in BP trajectories, defined as a level of BP beyond which the rate of BP rise accelerates.

Methods

We studied first-generation participants of the Framingham Heart Study, who compose 1 of the few existing cohorts with standardized BP measurements performed at frequent intervals (approximately every 2 years) during an extended period (1948 to 2005). In this setting, serial BP measurements collected across up to 28 examination cycles per participant allowed for precise estimates of long-term BP trajectories. The characteristics and study protocol of this original cohort (n = 5209) have been published previously. To reduce the potential effects of age, time, and birth cohort, we excluded individuals from analyses per the following criteria: participants who were older than 40 years at baseline, who had existing hypertension at baseline, who attended fewer than 3 examinations before hypertension onset, and/or who had hypertension onset before age 40 years or at or after age 80 years. The last criteria was applied because of the low number of individuals in these categories.

The institutional review board of Boston University Medical Center approved all protocols. Each participant provided informed consent.

At each examination, a physician used a mercury sphygmomanometer to perform 2 sequential BP measurements according to a standardized protocol; we calculated the mean of the 2 measurements as the final BP value. Hyper tension onset was defined as a BP level greater than or equal to 140/90 mm Hg or use of antihypertensive medication at 2 or more consecutive examinations. This approach was meant to reduce misclassification and represent a durable change in BP. Consistent with methods used in prior studies of disease onset, we also defined hypertension onset as the first examination at which hypertension criteria was met. For each participant meeting hypertension criteria, we truncated data at the time of hypertension onset. If a person was treated for hypertension at a given examination, we imputed systolic BP to be 10 mm Hg greater as an estimate of the expected BP if antihypertensive therapy were discontinued.

We categorized participants based on their age of hypertension onset (40-49 years, 50-59 years, 60-69 years, 70-79 years, or no onset), and compared baseline characteristics across these categories using 1-way analysis of variance and χ² tests. The associations between the predictor variable (age) and the response variable (systolic BP) were nonlinear, with associations demonstrating values at which the association of the predictor with the response changes abruptly (manifesting a change point). Therefore, for each age-based category of hypertension onset, we used an unadjusted segmented mixed model to fit the longitudinal systolic BP data collected to estimate change points in the association between advancing age and progressively increasing systolic BP leading up to hypertension onset. This method extends from simple segmented regression to permit application within a mixed-model framework; accordingly, the method includes random effects to accommodate longitudinal, repeated-measures data. The segmented mixed regression provides estimates and confidence intervals for the slopes before and after hypertension onset and the change point identified by age. To estimate confidence limits for the corresponding systolic BP for each change point, we performed 1000 bootstraps for each category and reported percentile limits to accommodate for non-parametric data distributions. We used the Cochran Q test to assess between-group heterogeneity in the estimates. We also plotted the systolic BP trajectories using restricted cubic splines.

All statistical analyses were performed using R version 3.3.1 (R Foundation for Statistical Computing). We considered a 2-sided P value of less than .05 statistically significant.
Results

Applying the study inclusion criteria to the 5209 individuals in the Framingham Original Cohort resulted in the exclusion of 3325 individuals who were older than 40 years at baseline, 471 with hypertension at baseline, 91 with fewer than 3 examinations attended before hypertension onset, and 70 who experienced hypertension onset either before age 40 years or at or after age 80 years. The final sample of 1252 individuals contributed 16,072 BP measurements collected once every 2 years.

The mean (SD) age of the total sample at baseline was 35.3 (2.7) years; 790 participants (63.1%) were women. Characteristics were similar across individuals categorized by age of hypertension onset (Table). We observed that individuals in each category generally maintained systolic BP measures below 120 to 125 mm Hg, above which systolic BP increased at a relatively rapid rate leading to overt hypertension (Figure 2). Systolic BP began to rise at a more rapid rate after reaching a mean level of 123.2 mm Hg (95% CI, 122.7–130.1 mm Hg) in people with hypertension onset at 40 to 49 years, 122.0 mm Hg (95% CI, 120.3–123.9 mm Hg) in those with onset between 50 and 59 years, 124.9 mm Hg (95% CI, 120.2–127.9 mm Hg) in those with onset between...
Figure 2. Observed Blood Pressure Trajectories Preceding Hypertension in the Framingham Heart Study Original Cohort

Discussion

Life-course BP trajectories in the general population are heterogeneous, with some individuals developing hypertension earlier or later in life or never at all. Nonetheless, we observed that among persons who develop hypertension during adulthood, systolic BP trajectories leading up to the onset of hypertension appear similar in pattern but variable in timing. In particular, systolic BP levels are generally stable until they approach approximately 120 to 125 mm Hg, after which systolic BP rises at a relatively rapid rate toward overt hypertension. This transitional systolic BP range was consistent whether hypertension developed in middle age or older age and could represent a critical threshold of extant vascular remodeling. Interestingly, this systolic BP range is concordant with recently published guidelines advocating use of the 130 mm Hg value for defining presence of hypertension.

Limitations

Notwithstanding strengths of the current study, including the availability of frequent standardized BP measurements performed in the same individuals serially throughout decades, certain limitations merit consideration. The mixed segmented model may not perform optimally for extremely noisy data or when the covariate effect is markedly linear or nonlinear, and the model cannot be approximated by a piecewise association. As with any statistical modeling, this approach may also lead to some oversimplification of data interpretation. Although the segmented regression lines fit our BP data reasonably well, BP trajectories throughout the entire life course are often highly variable, particularly at the individual level. Further studies are needed to validate and assess the generalizability of our findings, ideally in larger cohorts with serial BP measures performed beginning early in life.

Conclusions

Overall, our findings outline a possible framework for understanding life-course trends in arterial aging, which may have implications for managing BP in practice (Figure 1). In particular, our results suggest that the onset of clinically important BP elevation may be delayed despite aging. However, further investigations are still needed to unravel the sequence of hemodynamic and vascular changes occurring before hypertension onset. In addition, investigation is needed to determine the potential benefit of interventions aimed at preventing the onset of systolic BP rise, even within the normal systolic BP range, as part of efforts to reduce the overall burden of hypertension.
takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Niiranen, Henglin, Vasan, Larson, Cheng.

Acquisition, analysis, or interpretation of data: Niiranen, Henglin, Claggett, Muggeo, McCabe, Jain, Vasan, Cheng.

Drafting of the manuscript: Niiranen, Muggeo, McCabe, Cheng.

Critical revision of the manuscript for important intellectual content: Henglin, Claggett, Jain, Vasan, Larson, Cheng.

Statistical analysis: Niiranen, Henglin, Claggett, Muggeo, McCabe, Larson.

Obtained funding: Vasan, Cheng.

Administrative, technical, or material support: Jain, Vasan, Cheng.

Study supervision: Cheng.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Claggett reports receiving personal fees from AOBiome, Corvia, and Boehringer-Ingelheim outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by the American Heart Association (Dr Cheng), the Emil Aaltonen Foundation (Dr Niiranen), the Finnish Medical Foundation (Dr Niiranen), the Paavo Nurmi Foundation (Dr Niiranen), the National Heart, Lung and Blood Institute (grant N01HC25195 [the Framingham Heart Study]) and grant HHSN268201500001I (Dr Vasan), and National Institutes of Health grants RO1HL073328, RO1HL107385, and RO1HL126136 (Dr Vasan), RO0HL07642 and RO1HL131532 (Dr Cheng), and RO1HL134168 (Drs Jain and Cheng).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES


